

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

EXTENSION OF LONG STOP DATE AND COMPLETION ON DISCLOSEABLE TRANSACTION IN RELATION TO ACQUISITION OF A MEDICAL BEAUTY ANTI-AGING GROUP AND ISSUE OF SHARES UNDER GENERAL MANDATE

Reference is made to the announcement of the Company dated 12 August 2017 and the supplemental announcement of the Company dated 24 August 2017 in relation to a discloseable transaction for the acquisition of a medical beauty anti-aging group and issue of shares under general mandate (the “**Announcements**”). Unless the context otherwise states, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

As disclosed in the announcement dated 12 August 2017, if any conditions precedent to the Completion has not been fulfilled by the Long Stop Date (i.e. 31 August 2017), the Purchaser shall not be bound to proceed with the Acquisition, all rights and liabilities of the Vendors and the Purchaser shall cease and neither the Vendors and the Purchaser shall have any claim against the other save in respect of any antecedent breach by any Party under the Agreement. As additional time is required for the fulfillment of certain conditions precedent under the Agreement, the Parties to the Agreement entered into an extension letter dated 31 August 2017 to extend the Long Stop Date for fulfillment of the conditions precedent to 30 September 2017 or any other date as the Parties may agree in writing. Save as disclosed above, all other terms and conditions of the Agreement remain unchanged and in full force and effect in all respects.

The Board is pleased to announce that as the conditions precedent set out in the Agreement have been fulfilled, Completion took place on 9 September 2017. Immediately after Completion, the Target Group will become indirect subsidiaries of the Company and the financial results of the Target Group will be consolidated into the Company's consolidated financial statements. The Consideration Shares shall be issued and allotted to the Vendors and the HK\$50 million shall be paid to the Vendor A by the Purchaser within 30 calendar days after the Completion.

By order of the Board
**Common Splendor International
Health Industry Group Limited**
Cheung Wai Kuen
Chairman

Hong Kong, 9 September 2017

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang and Mr. Hou Kaiwen as non-executive Directors; and Mr. Mai Yang Guang and Mr. Lam Chi Wing as independent non-executive Directors.